Kezar Life Sciences (KZR) said Thursday it has received an unsolicited, non-binding takeover proposal from Concentra Biosciences for a cash consideration of $1.10 per share and is evaluating the offer.
The proposal includes a contingent value right to receive 80% of any net proceeds from Kezar's development programs or intellectual property, Kezar said.
Kezar shares were up 4% in recent Thursday premarket activity.
Price: 0.9089, Change: +0.04, Percent Change: +5.16
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments